| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Global cancer statistics.
|
CA Cancer J Clin
|
2011
|
185.92
|
|
2
|
Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions.
|
N Engl J Med
|
2007
|
15.40
|
|
3
|
Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study.
|
Lancet Oncol
|
2010
|
9.86
|
|
4
|
Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial.
|
Lancet Oncol
|
2005
|
9.67
|
|
5
|
Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial.
|
Lancet
|
2004
|
8.09
|
|
6
|
Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial.
|
Lancet
|
2006
|
7.83
|
|
7
|
High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up.
|
Br J Cancer
|
2006
|
6.59
|
|
8
|
FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP).
|
MMWR Morb Mortal Wkly Rep
|
2010
|
4.34
|
|
9
|
A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16.
|
J Natl Cancer Inst
|
1994
|
3.95
|
|
10
|
Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine.
|
J Natl Cancer Inst
|
2011
|
3.92
|
|
11
|
Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials.
|
Lancet
|
2007
|
3.10
|
|
12
|
Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial.
|
JAMA
|
2013
|
3.06
|
|
13
|
Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18.
|
Vaccine
|
2006
|
2.78
|
|
14
|
Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine.
|
Vaccine
|
2007
|
2.64
|
|
15
|
Development and duration of human papillomavirus lesions, after initial infection.
|
J Infect Dis
|
2005
|
2.51
|
|
16
|
Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only.
|
Vaccine
|
2006
|
2.37
|
|
17
|
Immune responses to human papillomavirus.
|
Vaccine
|
2006
|
2.37
|
|
18
|
Incidence, clearance and predictors of human papillomavirus infection in women.
|
CMAJ
|
2003
|
2.04
|
|
19
|
Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials.
|
Hum Vaccin
|
2009
|
1.75
|
|
20
|
Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study.
|
Hum Vaccin
|
2011
|
1.65
|
|
21
|
Mechanisms used by human papillomaviruses to escape the host immune response.
|
Curr Cancer Drug Targets
|
2007
|
1.26
|
|
22
|
Immunogenicity and reactogenicity of alternative schedules of HPV vaccine in Vietnam: a cluster randomized noninferiority trial.
|
JAMA
|
2011
|
1.12
|
|
23
|
Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice.
|
J Virol
|
2003
|
1.12
|
|
24
|
Role of AS04 in human papillomavirus vaccine: mode of action and clinical profile.
|
Expert Opin Biol Ther
|
2011
|
1.07
|
|
25
|
Age of recipient and number of doses differentially impact human B and T cell immune memory responses to HPV vaccination.
|
Vaccine
|
2012
|
1.04
|
|
26
|
HPV vaccine: an overview of immune response, clinical protection, and new approaches for the future.
|
J Transl Med
|
2010
|
1.03
|
|
27
|
Evidence of immune memory 8.5 years following administration of a prophylactic human papillomavirus type 16 vaccine.
|
J Clin Virol
|
2011
|
1.01
|
|
28
|
Maintenance of serological memory.
|
Biol Chem
|
2008
|
0.98
|
|
29
|
Human papillomavirus vaccines: WHO position paper.
|
Biologicals
|
2009
|
0.96
|
|
30
|
Human papillomavirus genotype prevalence in cervical biopsies from women diagnosed with cervical intraepithelial neoplasia or cervical cancer in Fiji.
|
Sex Health
|
2011
|
0.95
|
|
31
|
Characterization of the HPV-specific memory B cell and systemic antibody responses in women receiving an unadjuvanted HPV16 L1 VLP vaccine.
|
Vaccine
|
2010
|
0.94
|
|
32
|
The E2F5 repressor is an activator of E6/E7 transcription and of the S-phase entry in HPV18-associated cells.
|
Oncogene
|
2010
|
0.80
|
|
33
|
Human papillomavirus vaccine safety in Australia: experience to date and issues for surveillance.
|
Sex Health
|
2010
|
0.79
|
|
34
|
Serologic response to human papillomavirus 16 among Australian women with high-grade cervical intraepithelial neoplasia.
|
Int J Gynecol Cancer
|
2006
|
0.79
|
|
35
|
The high burden of cervical cancer in Fiji, 2004-07.
|
Sex Health
|
2013
|
0.78
|